^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
Title:

A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated BRAFV600/NRASQ61R/K/L wild-type melanoma (TraMel-WT): Interim efficacy and safety results.

Published date:
05/19/2021
Excerpt:
Four out of 6 OR are observed in pts with MAPK-pathway activating mutations (3 class II BRAF and 1 GNAQ mutation)....In this two-stage phase 2 trial, T plus LD-D was found to have promising antitumor activity and acceptable toxicity in pts with advanced pretreated BRAFV600/NRASQ61R/K/L wt melanoma, especially in the presence of identifiable somatic MAPK-pathway activating mutations.
DOI:
10.1200/JCO.2021.39.15_suppl.9529
Trial ID: